AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges.

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-01-08 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S495364

Zhifang He, Wenyu Li

{"title":"AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges.","authors":"Zhifang He, Wenyu Li","doi":"10.2147/DMSO.S495364","DOIUrl":null,"url":null,"abstract":"<p><p>With the aging of China's population and lifestyle changes, the number of patients with type 2 diabetes (T2D) has surged, posing a significant challenge to the public health system. This study explores the application and effectiveness of artificial intelligence (AI) technology in T2D management from a Chinese perspective. AI demonstrates substantial potential in personalized treatment planning, real-time monitoring and early warning, telemedicine, and health management. It not only enhances the precision and convenience of treatment but also aids in preventing and managing complications. Despite challenges in data privacy, technology popularization, standardization, and regulation, AI technology's continuous maturation and expanded application suggest its increasingly pivotal role in T2D management. In the future, through interdepartmental collaboration, policy support, and cultural adaptation, AI is poised to bring revolutionary changes to diabetes management in China and globally.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"85-92"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718508/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S495364","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

With the aging of China's population and lifestyle changes, the number of patients with type 2 diabetes (T2D) has surged, posing a significant challenge to the public health system. This study explores the application and effectiveness of artificial intelligence (AI) technology in T2D management from a Chinese perspective. AI demonstrates substantial potential in personalized treatment planning, real-time monitoring and early warning, telemedicine, and health management. It not only enhances the precision and convenience of treatment but also aids in preventing and managing complications. Despite challenges in data privacy, technology popularization, standardization, and regulation, AI technology's continuous maturation and expanded application suggest its increasingly pivotal role in T2D management. In the future, through interdepartmental collaboration, policy support, and cultural adaptation, AI is poised to bring revolutionary changes to diabetes management in China and globally.

查看原文本刊更多论文

中国人工智能驱动的2型糖尿病管理：机遇与挑战

随着中国人口老龄化和生活方式的改变，2 型糖尿病（T2D）患者人数激增，给公共卫生系统带来了巨大挑战。本研究从中国的视角探讨了人工智能（AI）技术在 T2D 管理中的应用和效果。人工智能在个性化治疗计划、实时监测和预警、远程医疗和健康管理等方面展现出巨大潜力。它不仅提高了治疗的精准度和便利性，还有助于预防和管理并发症。尽管在数据隐私、技术普及、标准化和监管方面存在挑战，但人工智能技术的不断成熟和应用范围的不断扩大表明，它在 T2D 管理中发挥着越来越关键的作用。未来，通过跨部门合作、政策支持和文化适应，人工智能将为中国乃至全球的糖尿病管理带来革命性的变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.